NCT02529579View on ClinicalTrials.gov

Safety and Efficacy Evaluation of iAPA-DC/CTL Combined Gemcitabine Therapy on Advanced Pancreatic Cancer

PHASE1/PHASE2UnknownINTERVENTIONAL
Enrollment

187

Participants

Timeline

Start Date

June 30, 2015

Primary Completion Date

December 31, 2018

Study Completion Date

December 31, 2019

Conditions
Carcinoma, Pancreatic Ductal
Interventions
OTHER

iAPA-DC/CTL adoptive cellular immunotherapy

twice DC cell infusion and CTL cell infusion for 6 times

DRUG

Gemcitabine

standard Gemcitabine therapy

Trial Locations (1)

200433

RECRUITING

Changhai Hospital, Second Military Medical University, Shanghai

Sponsors
All Listed Sponsors
collaborator

ImmunoGene Biotechology Co.,Ltd

UNKNOWN

lead

Changhai Hospital

OTHER